Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alzheimer’s and brain imaging

Executive Summary

The role of brain imaging as an outcome measure in Phase III Alzheimer's Disease trials will be discussed at a joint meeting of FDA's Peripheral & Central Nervous System Drugs and Medical Imaging Drugs Advisory Committees Nov. 18. On Nov. 19, the committees will review Down State Medical's positron emission tomography agent F18 fluoro-D-glucose for imaging in Alzheimer's Disease. The meeting will take place at the Holiday Inn, Gaithersburg, Md...

You may also be interested in...



Down State Medical F18 FDG review cancelled

A Nov. 19 review of Down State Medical's positron emission tomography agent F18 fluoro-D-glucose (FDG) for the diagnosis and/or identification of Alzheimer's disease progression has been cancelled. FDA's Peripheral & Central Nervous System Drugs Committee still will discuss the use of Alzheimer's brain imaging as a surrogate endpoint in clinical trials on Nov. 18 (1"The Pink Sheet" Sept. 30, In Brief)...

Podcast: The Week In European Consumer Health Industry News, 8 March 2021

HBW editors Tom Gallen and David Ridley discuss the big issues in the European consumer health market from the past week. In this edition, they delve into probiotics, digital health and Bayer’s recent turnaround.

The Ins And Outs Of The EU's Approach To COVID-19 Vaccine Procurement & Exports

EU trade expert Hervé Jouanjean considers the reasoning behind the EU’s vaccine procurement approach and Italy's decision to block exports of AstraZeneca's  COVID-19 vaccine.

UsernamePublicRestriction

Register

OM010563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel